| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Gross profit | 2,004 | 1,397 | 684 | - |
| Research and development | 275 | 186 | 94 | - |
| Marketing and selling | 717 | 497 | 225 | - |
| General and administrative | 375 | 244 | 116 | - |
| Interest expense, net of capitalized interest | 140 | 88 | 40 | - |
| Other expense, net | -23 | -23 | -12 | - |
| Income tax (benefit) expense | -9 | 7 | -7 | - |
| Total other significant segment expenses | 1,521 | 1,045 | 480 | - |
| Other expenses (income) | 439 | 274 | 137 | - |
| Net income | 44 | 78 | 67 | 346 |
| Depreciation and amortization | 506 | 330 | 161 | 498 |
| Goodwill impairment | - | - | - | 0 |
| Stock-based compensation expense | 52 | 35 | 15 | 40 |
| Asset impairment and write-down charges | 24 | 0 | - | 76 |
| Gain on divestiture | 0 | - | - | 640 |
| Sold portion of royalty revenue | 10 | 4 | - | - |
| Proceeds from interest rate swap settlements | - | - | - | 5 |
| Interest on liability for sale of future revenue | 20 | 7 | - | - |
| Changes in operating assets and liabilities, net of acquisitions and divestitures | 126 | 185 | 237 | -93 |
| Other non-cash operating activities, net | -58 | -28 | -10 | -54 |
| Net cash provided by operating activities | 452 | 233 | -4 | 364 |
| Net purchases of property and equipment and software | 214 | 122 | 65 | 100 |
| Cash paid for acquisitions | - | - | - | 5 |
| Proceeds from divestitures | 9 | 9 | 9 | 1,294 |
| Proceeds from previous sale of shawnee and speke facilities (see note 4) | - | - | - | 66 |
| Purchases of intangible assets | - | - | - | 8 |
| Other investing activities, net | 10 | 1 | 2 | -1 |
| Net cash (used for) provided by investing activities | -215 | -114 | -58 | 1,248 |
| Proceeds from facility-Revolving Credit Facility | 125 | 125 | 125 | 50 |
| Repayments of facility-Revolving Credit Facility | 125 | 125 | 125 | 250 |
| Proceeds from facility-Securitization Facility | 125 | 125 | 125 | 170 |
| Repayments of facility-Securitization Facility | 125 | 125 | 40 | 170 |
| Proceeds from issuance of long-term debt | 0 | - | - | 350 |
| Repayments of long-term borrowings | 562 | 374 | 13 | 1,587 |
| Proceeds from sale of future revenue, net of transaction costs | 290 | 290 | - | - |
| Other financing activities, net | 15 | -20 | -20 | -23 |
| Net cash used for financing activities | -257 | -104 | 52 | -1,460 |
| Effect of exchange rate changes on cash and cash equivalents | 57 | 56 | 29 | -14 |
| Net increase in cash and cash equivalents | 37 | 71 | 19 | 138 |
| Cash and cash equivalents at beginning of period | 468 | 468 | 468 | 352 |
| Cash and cash equivalents at end of period | 505 | 539 | 487 | 490 |
Elanco Animal Health Inc (ELAN)
Elanco Animal Health Inc (ELAN)